DaVita Inc. (DVA)

FairStock Score: 63/100 — STEADY

Key Financials

Strengths

• Defensive, recurring revenue model from essential dialysis services with 78,000 employees serving chronic kidney patients
• Strong free cash flow generation of $1.1B annually providing real cash returns to shareholders
• Low business volatility (Beta 0.93) and stable demand insulated from economic cycles
• Respectable Piotroski F-Score of 7/9 indicating reasonable financial quality indicators
• Reasonable valuation at P/E 15.70 on surface, though masked by leverage

Concerns

• Critically weak Altman Z-Score of 0.72 signals balance sheet distress and high bankruptcy risk
• Extreme leverage with D/E ratio of 11.11 creates fragility; profits go to servicing debt, not reinvestment
• Rich EV/EBITDA multiple of 31.21x for a slow-growth mature business—little room for disappointment
• Low ROCE of 7.32% despite high ROE reveals leverage is inflating returns rather than operational excellence

AI Analysis

DaVita presents a classic defensive healthcare business with predictable cash flows, but the financial structure gives me pause. Let me be direct: this is a mature, essential service company operating in a regulated market with 78,000 employees serving chronic kidney disease patients. The business generates $1.1B in free cash flow annually on $3.6B quarterly revenue, demonstrating real earning power. However, I'm troubled by several metrics. The Altman Z-Score of 0.72 sits dangerously in distress territory—this suggests balance sheet fragility. The debt-to-equity ratio of 11.11 is alarmingly high; this isn't a conservative capital structure. The EV/EBITDA multiple of 31.21x is rich for a slow-growth utility-like business, implying the market has priced in perfection. The Piotroski F-Score of 7/9 is respectable but not exceptional. What concerns me most: the ROE of 64.85% appears inflated by leverage rather than genuine operational excellence—the low ROCE of 7.32% confirms this. The FairStock Score of 53/100 is middling at best. At $152.56 with a P/E of 15.70 and FCF yield of only 3.9%, I'm not finding the margin of safety Graham would demand. The 6.47% net margin is thin for a healthcare services provider. This is a business worth owning at the right price—the recurring revenue model has merit—but I'd need to see the stock trade 25-30% lower, demonstrate debt reduction, or show accelerating operational improvements before deploying capital here.

Bull Case

DaVita operates an essential, non-discretionary healthcare service with predictable cash flows and pricing power supported by Medicare/Medicaid reimbursement. Management may execute an aggressive debt paydown strategy, meaningfully improving financial safety and unlocking shareholder value at current cash generation levels.

Bear Case

The unsustainable debt structure (D/E 11.11) combined with distress-level Z-Score (0.72) creates existential risk if dialysis volumes decline or reimbursement rates compress. A recession or healthcare policy shift could force asset sales or equity dilution, devastating shareholders.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer